As the global medical and laboratory industries gather in Düsseldorf for MEDICA 2026, discussions around diagnostic technologies, laboratory quality, and reliable testing solutions continue to attract attention.

Taking place from November 16–19, MEDICA is one of the world’s major international medical trade fairs, bringing together manufacturers, distributors, healthcare professionals, and industry experts.

Among the technologies supporting modern laboratory quality control, Total Organic Carbon (TOC) analysis has an important role. While TOC testing is widely recognized today, its development also created a specific need for reliable surface sampling tools: TOC Sampling Swabs.

The Origins of TOC Testing: Why Was It Developed?

Before TOC analysis became widely available, scientists needed more efficient ways to measure organic contamination in water and other samples.

Traditional methods such as Biochemical Oxygen Demand (BOD) and Chemical Oxygen Demand (COD) were commonly used to evaluate organic pollution. However, these approaches had limitations. BOD testing could take several days, while COD analysis required chemical reagents and additional processing.

The development of Total Organic Carbon analysis during the 1960s offered another approach.

Instead of measuring oxygen consumption, TOC analysis measures the carbon contained in organic compounds. In a typical analytical process, organic carbon is converted into carbon dioxide, which is then measured by an analytical instrument.

This approach provides a direct quantitative measurement of organic carbon and has become an important tool in environmental analysis, water quality monitoring, and pharmaceutical quality control.

As analytical technology advanced, TOC testing gradually expanded beyond water analysis into applications requiring the monitoring of organic residues on equipment and other surfaces.

Why Did the Pharmaceutical Industry Need TOC Sampling Swabs?

The expansion of TOC analysis into pharmaceutical manufacturing introduced a new challenge: measuring organic residues on equipment surfaces.

During pharmaceutical production, active ingredients, excipients, and cleaning agents may leave residual materials on manufacturing equipment. If cleaning is insufficient, these residues may create cross-contamination risks between production batches.

Cleaning validation therefore became an essential part of pharmaceutical quality management.

Traditionally, manufacturers have used two major approaches to collect samples for cleaning validation:

Rinse Sampling

Rinse sampling uses a suitable liquid to collect residues from equipment surfaces. It is useful for assessing larger areas and internal equipment surfaces that may be difficult to access directly.

However, rinse sampling may not always identify contamination at specific locations.

Swab Sampling

Swab sampling involves physically wiping a defined surface area to collect potential residues. It allows operators to target specific locations, such as equipment joints, corners, and other accessible hard-to-reach areas.

These two approaches are complementary. The appropriate method depends on equipment design, sampling accessibility, and the validated cleaning procedure.

As TOC analysis became an established method for evaluating organic residues, laboratories needed sampling materials suitable for this particular analytical application.

This created the demand for specialized TOC Sampling Swabs.

The Emergence of TOC Sampling Swabs

An important consideration in TOC analysis is that the sampling tool itself can influence the measurement.

Unlike ordinary cleaning applications, TOC sampling requires careful control of background organic carbon. If a conventional swab releases organic substances during extraction, it may contribute additional carbon to the sample and interfere with the analytical result.

This is why specialized TOC Sampling Swabs were developed.

They are designed to collect surface residues while minimizing the potential contribution of organic carbon from the sampling material itself.

Several performance factors are important:

• Low TOC Background: Minimizing additional organic carbon introduced by the swab.
• Residue Recovery: Supporting the collection and subsequent release of organic residues from the sampled surface.
• Material Compatibility: Ensuring compatibility with the extraction solution and analytical procedure.
• Sampling Consistency: Supporting repeatable sampling conditions across different locations.

By the early 2000s, specialized TOC swabbing kits were already commercially available. In 2006, research published in the PDA Journal of Pharmaceutical Science and Technology specifically examined the validation of TOC swab sampling and testing methods.

This reflects an important development in pharmaceutical quality control: reliable analytical results depend not only on the instrument but also on the quality of sample collection.

Why Ordinary Swabs Cannot Simply Replace TOC Sampling Swabs

A common question is whether an ordinary surface sampling swab can be used for TOC testing.

The answer depends on the sampling material and the analytical requirements.

Ordinary swabs may be designed for cleaning, microbiological sampling, or general specimen collection. These applications do not necessarily require the same control over background organic carbon.

For TOC applications, the sampling material must be evaluated to ensure that it does not introduce unacceptable interference.

For example, a swab with excessive extractable organic carbon could produce an elevated background reading, making it more difficult to distinguish the carbon collected from the actual equipment surface.

This is particularly important when laboratories are measuring very low levels of organic residues.

Therefore, selecting a suitable TOC Sampling Swab is part of establishing a reliable and validated sampling procedure.

How TOC Sampling Swabs Support Modern Laboratory Workflows

Today, TOC Sampling Swabs are used in applications where surface residues need to be collected for subsequent total organic carbon analysis.

Typical applications include:

• Pharmaceutical equipment cleaning validation.
• Organic residue monitoring on manufacturing surfaces.
• Laboratory surface sampling.
• Quality control procedures in pharmaceutical and biotechnology facilities.
• Selected industrial surface testing applications.

A typical workflow involves defining the sampling area, wiping the designated surface with a suitable swab, transferring the swab into an appropriate extraction solution or sampling container, and analyzing the extracted sample using a qualified TOC analyzer.

In some situations, sampling locations may be difficult to access using a standard swab handle. Specialized accessories, such as TOC Swab Extension Handles, can help operators reach selected surfaces and improve sampling convenience.

HCY: Supporting Reliable TOC Sampling Solutions

As the global medical and laboratory industries continue to develop, reliable sampling consumables remain an important part of quality control.

Shenzhen Huachenyang Technology Co., Ltd. (HCY), established in 2008, is a professional medical device and laboratory consumables manufacturer integrating research and development, manufacturing, and sales.

HCY provides TOC Sampling Swabs for surface sampling applications, supporting laboratory workflows involving organic residue collection and subsequent TOC analysis.

Together with compatible sampling accessories, including TOC Swab Extension Handles, HCY focuses on providing practical sampling solutions for laboratory and industrial applications.

As MEDICA 2026 brings together professionals from across the international medical industry, HCY continues to focus on the importance of reliable sampling products and manufacturing quality.

Reliable analysis starts with reliable sampling.

The 2026 Ebola outbreak in the Democratic Republic of the Congo (DRC) has surpassed 10,000 confirmed cases, highlighting the importance of timely case identification, reliable laboratory testing, and effective infection prevention.

According to the U.S. Centers for Disease Control and Prevention (CDC), as of October 28, 2026, the DRC had reported 10,274 confirmed cases and 4,992 confirmed deaths. The outbreak has affected eight provinces, while related cases have also been reported in other countries.

The outbreak is caused by Bundibugyo virus, an Ebola virus species that requires particular attention when selecting diagnostic methods. These developments reinforce the need for healthcare institutions, laboratories, and diagnostic suppliers to understand what different Ebola tests can—and cannot—establish.

Source: CDC — Ebola Outbreak: Current Situation

Why Does Accurate Ebola Testing Matter?

Ebola virus disease can initially present with symptoms such as fever, fatigue, headache, and muscle pain. These symptoms overlap with those of other infectious diseases, making clinical assessment alone insufficient to confirm an infection.

Laboratory testing plays an essential role in identifying suspected cases and supporting public health responses. However, selecting a suitable test requires more than considering speed or convenience.

Healthcare institutions should evaluate several factors:

• Target virus: Does the test detect the specific Ebola virus species associated with the suspected infection?
• Detection method: Is the test based on antigen detection or molecular methods such as RT-PCR?
• Performance evidence: Are sensitivity, specificity, and other performance claims supported by appropriate data?
• Specimen requirements: Is the intended specimen type compatible with the test’s validated instructions?
• Regulatory status: Is the product authorized, cleared, or otherwise appropriately evaluated for its intended use and destination market?

These considerations are particularly important during an outbreak involving a virus species for which diagnostic options may differ from those available for other Ebola virus species.

Ebola Antigen Tests and Molecular Diagnostics: Understanding the Difference

Ebola diagnostic tests are not interchangeable. Antigen rapid diagnostic tests detect specific viral proteins, while molecular tests such as RT-PCR detect viral genetic material.

Both approaches have distinct technical requirements, performance characteristics, and limitations. A rapid result does not automatically mean that a test is suitable for every stage of infection or every Ebola virus species.

The current Bundibugyo virus outbreak makes this distinction especially important. In its May 22, 2026 recommendations, the Africa Centres for Disease Control and Prevention (Africa CDC) reported that the antigen rapid diagnostic tests assessed at that time did not meet the required target product profile for use in the current outbreak response.

This finding highlights why diagnostic products must be evaluated against the specific pathogen, intended use, and available evidence rather than selected solely on the basis of their product names or advertised speed.

Source: Africa CDC — Molecular Diagnostic Tests (RT-PCR) for Ebola Virus Bundibugyo Strain

What Should Laboratories Consider When Choosing an Ebola Test Kit?

For laboratories, healthcare organizations, distributors, and medical procurement teams, evaluating an Ebola test kit should begin with documented suitability rather than brand recognition alone.

A structured evaluation should include the manufacturer’s technical documentation, intended-use statement, validated specimen types, analytical and clinical performance evidence, quality-management information, and applicable regulatory documentation.

Supply reliability, storage conditions, shelf life, packaging, and technical support may also be important when preparing for public health emergencies.

For procurement teams comparing an Ebola virus test kit manufacturer, these details provide a more meaningful basis for decision-making than unsupported claims that a product is the best or most accurate option available.

HCY: A Diagnostic Product Manufacturer to Evaluate

Shenzhen Huachenyang Technology Co., Ltd. (HCY) is a medical diagnostic and consumables manufacturer established in 2008, with business activities spanning research and development, manufacturing, and sales.

HCY lists an Ebola Virus Antigen Rapid Test Kit among its diagnostic products. For laboratories and professional buyers evaluating this product, the appropriate next step is to review its documented detection target, intended use, specimen requirements, performance evidence, and applicable regulatory status.

In particular, buyers should confirm whether the product has evidence supporting detection of Bundibugyo virus before considering it for applications related to the current outbreak. A product’s designation as an Ebola antigen test does not, by itself, establish suitability for every Ebola virus species or clinical setting.

For additional product information and supplier enquiries, visit HCY’s official website.

Looking Ahead: Better-Informed Diagnostic Decisions

The 2026 Ebola outbreak demonstrates that effective diagnostic preparedness depends on more than access to testing products. It requires appropriate test selection, reliable laboratory processes, evidence-based evaluation, and coordination between healthcare institutions and diagnostic suppliers.

As the outbreak continues to evolve, laboratories and procurement teams should follow updates from the WHO, CDC, and Africa CDC while reviewing the suitability and documentation of diagnostic products for their intended applications.

For HCY and other diagnostic manufacturers, transparent product information and verifiable performance evidence are essential to helping professional buyers make informed decisions.

Keep Hands Clean

From sharing treats to touching door handles and decorations, hands come into contact with many surfaces throughout Halloween activities. Washing hands with soap and water at key moments, especially before eating and after using the restroom, helps reduce the spread of germs.

Clean Shared Surfaces

Party tables, frequently touched objects, and shared activity areas deserve regular attention. Cleaning visibly dirty surfaces and following appropriate disinfection instructions can support a healthier environment at home, in schools, and at community events.

Make Hygiene Part of the Celebration

Good hygiene does not have to interrupt the fun. Keeping handwashing supplies available, handling food safely, and maintaining clean shared spaces are practical steps that everyone can follow.

At Huachenyang (HCY), we believe that protecting health starts with attention to everyday details. As a medical device manufacturer specializing in sampling products and related healthcare solutions, HCY supports healthcare professionals and partners with products designed for reliable sample collection and hygiene-related applications.

This Halloween, enjoy the treats, embrace the traditions, and remember: small habits can make a meaningful difference in keeping our communities healthier.

Happy Halloween 2026 from HCY!

Early Flu Activity Is Rising in the United States

According to the U.S. Centers for Disease Control and Prevention (CDC), influenza activity remained low nationally in the week ending October 10, 2026, but several indicators had been increasing since late August and early September.

The percentage of clinical laboratory specimens testing positive for influenza rose from 3.9% in the previous week to 5.0%. Although these figures do not indicate how severe the full season will be, they demonstrate why respiratory virus surveillance and diagnostic readiness matter early in the season.

The World Health Organization (WHO) estimates that seasonal influenza causes approximately one billion infections worldwide each year, including 3–5 million cases of severe illness. These long-term estimates underline the continuing global burden of influenza, even though the timing and severity of each season vary.

Why the 2026–2027 Season Deserves Attention

Influenza viruses continue to evolve, which is why seasonal vaccine compositions are reviewed and updated regularly. For the 2026–2027 Northern Hemisphere season, WHO recommended updated vaccine virus components based on global surveillance data. In the United States, all three components of the seasonal influenza vaccine were updated compared with the previous season.

These updates reflect the changing nature of influenza viruses, but they do not mean that a more severe season is inevitable. Ongoing surveillance and appropriate diagnostic testing remain important for understanding which viruses are circulating and supporting clinical decisions.

Reliable Testing Starts Before the Laboratory

Accurate respiratory testing depends on more than laboratory instruments and diagnostic assays. Specimen collection, handling, and transport are also important parts of the testing process.

The appropriate swab must match the intended specimen type and diagnostic method. Flocked swabs are used in many respiratory specimen collection workflows, while viral transport medium (VTM) may be required when specimens need to be transported to another testing facility.

Storage conditions, transport time, and specimen requirements should always follow the applicable test manufacturer’s instructions and laboratory procedures. Poor handling can compromise specimen quality and may lead to repeat collection or testing delays.

Supporting Respiratory Specimen Collection and Transport

As a medical device manufacturer specializing in specimen collection and transport products, Huachenyang (HCY)provides solutions for healthcare and laboratory applications, including flocked swabs and viral transport medium (VTM).

For diagnostic laboratories, healthcare providers, and medical device distributors, selecting compatible collection materials and maintaining standardized handling procedures can help support a consistent respiratory testing workflow throughout flu season.

As influenza activity evolves during the 2026–2027 season, preparation begins with reliable surveillance, appropriate testing, and careful attention to every step from specimen collection to laboratory analysis.

Sources:

• U.S. CDC, Weekly U.S. Influenza Surveillance Report, Week 40, 2026
• WHO, Recommendations for Influenza Vaccine Composition for the 2026–2027 Northern Hemisphere Season
• U.S. CDC, 2026–2027 Flu Season

Dengue may receive less attention when outbreak headlines fade, but the risk has not disappeared. According to the World Health Organization (WHO), approximately 2.2 million dengue cases and more than 1,100 deaths were reported across 97 countries and territories between January and August 2026. Although global reported cases were lower than in the previous two years, several countries continued to experience significant outbreaks.

Bangladesh is a recent reminder of this ongoing threat. In October 2026, Reuters reported a worsening outbreak, with more than 90,000 hospitalizations and hundreds of deaths reported since the beginning of the year. The situation highlights why dengue awareness must remain a public health priority, even when global trends appear to improve.

Recognizing the Risk Beyond the Headlines

Dengue is transmitted primarily by infected Aedes mosquitoes. Fever, headache, muscle pain, and joint pain are common symptoms, but early dengue can resemble other febrile illnesses. Some patients may develop severe dengue, making timely medical assessment essential.

Importantly, warning signs can appear after a fever begins to subside. Severe abdominal pain, persistent vomiting, bleeding, or unusual weakness require urgent medical attention. A falling temperature alone does not guarantee recovery.

Prevention Begins with Awareness and Action

Reducing mosquito breeding sites is a practical first step. Empty standing water from containers, maintain clean surroundings, use appropriate mosquito repellents, and follow local public health guidance. Anyone with a suspected infection should seek medical advice rather than relying on symptoms alone.

Accurate diagnosis also matters. Depending on the stage of illness, healthcare professionals may use molecular tests, NS1 antigen tests, or antibody tests. Reliable diagnostic workflows depend on selecting appropriate tests, following specimen collection and handling requirements, and interpreting results in the clinical context.

Supporting Better Diagnostic Preparedness

At Huachenyang (HCY), we recognize the importance of reliable specimen collection and well-managed diagnostic workflows in healthcare. Through our work in medical specimen collection products and diagnostic consumables, we support the broader laboratory and healthcare ecosystem.

Dengue prevention requires more than a response to an outbreak. It depends on public awareness, responsible community action, timely medical assessment, and reliable diagnostic processes working together.

Dengue may fade from the headlines, but vigilance should never fade from our daily lives.

When Does a Short Swab Design Matter?

In workflows involving limited operating space, small sample containers, or close-range manual handling, a shorter swab may offer practical advantages. Its compact shaft can make the tool easier to position and handle in certain setups, depending on the sampling procedure and operator requirements.

However, swab selection should not rely on length alone. The sampling head dimensions, shaft material, specimen type, and compatibility with downstream testing methods must also be considered.

Choosing the Right Swab for IVD Applications

For in vitro diagnostic (IVD) applications, laboratories should evaluate swab specifications against their intended sampling procedures. Key considerations include specimen compatibility, sample release performance, transport conditions, and the requirements of the relevant assay.

A shorter design is not universally better; its value depends on whether its dimensions suit the intended workflow.

HCY CY-96001 Short Flocked Swab

HCY’s CY-96001 Short Flocked Swab is designed for IVD-related sampling applications. Its compact format and available size options provide choices for different sampling requirements. The product is labeled non-sterile, so users should verify that its status and specifications meet the requirements of their intended application.

By considering swab dimensions alongside specimen requirements and testing workflows, laboratories and diagnostic manufacturers can make more informed decisions when selecting sampling consumables.

For detailed specifications and application guidance, contact HCY.

For Huachenyang, National Day is also a meaningful moment to reflect on our journey and the people who have been part of it.

Founded in Shenzhen in 2008, Huachenyang has grown into a medical device manufacturer focused on in vitro diagnostics (IVD), integrating research and development, manufacturing and sales. Over the years, we have continued to develop our capabilities while building long-term relationships with customers and partners around the world.

From Shenzhen to global markets, every step of our journey has been shaped by cooperation, trust and a shared commitment to healthcare.

Today, Huachenyang continues to move forward with the same mission: developing reliable medical products, supporting our partners and contributing to better healthcare.

National Day is a celebration of where we have come from, but also a reminder to keep looking ahead.

As China celebrates National Day 2026, Huachenyang sincerely thanks our customers, partners and friends around the world for being part of our journey.

May this National Day bring happiness, meaningful moments with family and renewed inspiration for the future.

From China to the world, Huachenyang will continue moving forward together with our partners toward a healthier future.

Happy National Day 2026!

Huachenyang — Health Care for You, Is Our Forever Mission.

As the full moon rises this Mid-Autumn Festival, Shenzhen Huachenyang Technology Co., Ltd. (HCY) would like to extend our warmest wishes to our customers, partners, and friends around the world.

In Chinese culture, the Mid-Autumn Festival is a time for reunion. Families gather under the full moon, share mooncakes, and take a moment to appreciate the people who matter most. The round moon has long been a symbol of togetherness, connection, and good wishes.

For HCY, these ideas have a special meaning.

Since 2008, we have been working in the field of in vitro diagnostics and medical consumables, supporting healthcare and laboratory applications with reliable sample collection and diagnostic products. Behind every product is a simple purpose: helping healthcare professionals collect, preserve, and handle samples more effectively.

As our customers and partners work across different countries and time zones, the Mid-Autumn Festival also reminds us that meaningful connections can cross borders.

This year, as we look toward the moon from different places around the world, HCY is grateful for the trust and cooperation we have built with our global partners.

May this Mid-Autumn Festival bring you and your loved ones health, happiness, and reunion.

Happy Mid-Autumn Festival from HCY!

Health Care for You Is Our Forever Mission.

For healthcare professionals, understanding why drying matters can help improve the consistency and safety of skin preparation.

What Happens After CHG Is Applied?

Many CHG skin-preparation products combine chlorhexidine with alcohol.

After the solution is applied, the alcohol begins to evaporate from the skin. At the same time, chlorhexidine remains on the treated surface and provides its intended antiseptic activity.

If the solution is removed before it has dried, the skin may not receive the intended exposure to the formulation.

This is why healthcare professionals are generally instructed to allow the preparation to air dry rather than wiping it away.

Why Is Drying Especially Important in the Operating Room?

Alcohol-based antiseptics require additional attention because wet alcohol can be flammable.

During surgery, equipment such as electrosurgical devices, lasers, or other potential ignition sources may be present. If alcohol-based antiseptic solution remains wet on the patient’s skin or has pooled around the patient, it can increase fire risk.

Allowing the preparation to dry completely helps reduce this risk.

The important point is that drying is not simply about waiting for the skin to “feel dry.” Healthcare professionals should follow the specific product instructions and ensure that excess solution has not collected beneath the patient or in skin folds.

Is There a Universal CHG Drying Time?

No.

A common mistake is to assume that every CHG applicator should have the same drying time. In reality, drying can be affected by several factors, including:

• CHG and alcohol formulation
• Amount of solution applied
• Size of the preparation area
• Skin folds or anatomical contours
• Temperature and airflow
• Amount of solution that has pooled

Therefore, a fixed drying time should not be applied to every CHG product.

For example, a larger preparation area using a higher volume of solution may naturally require more time to dry than a smaller preparation area.

The manufacturer’s instructions for use (IFU) should always take priority.

Why Should Healthcare Professionals Avoid Blowing or Wiping?

It may seem convenient to speed up the process by wiping the skin or blowing air across it. However, these actions can interfere with the intended preparation process.

Wiping can remove antiseptic solution from the skin before the preparation is complete. Blowing directly onto the prepared area can also introduce unnecessary contamination.

The safer approach is simple: apply the product according to its validated instructions and allow it to dry naturally.

What About Procedures Near Sensitive Tissues?

Drying becomes particularly important when skin antisepsis is performed before procedures where residual antiseptic could potentially reach sensitive tissues.

Research involving CHG-alcohol preparations before neuraxial procedures has drawn attention to the importance of allowing the antiseptic to dry before needle insertion.

This does not mean that every CHG product has the same clinical restrictions. The formulation, concentration, application site, and intended use all matter.

For this reason, healthcare professionals should always follow the specific product labeling and applicable clinical protocols.

How Does the Applicator Design Affect Drying?

The applicator itself can influence how consistently the solution is distributed.

A well-designed CHG applicator should allow controlled delivery and help healthcare professionals achieve appropriate coverage without unnecessarily saturating the skin.

Using excessive solution does not automatically provide better antisepsis. It can instead increase the amount of liquid that must evaporate and may increase the possibility of pooling.

This is one reason that applicator volume and application technique should be matched to the intended preparation area.

As a medical-device manufacturer, Huachenyang (HCY) focuses on applicator design and manufacturing consistency to support practical clinical skin-preparation workflows.

A Practical Rule for CHG Skin Preparation

The key principle is straightforward:

Apply → Cover the required area → Allow to air dry → Proceed according to the clinical protocol.

Drying should not be treated as an insignificant waiting period. It is part of the skin-preparation process and, with alcohol-based CHG products, an important safety consideration.

For healthcare professionals using CHG applicators, following the product IFU, avoiding excessive solution, preventing pooling, and allowing adequate natural drying can help make skin antisepsis more consistent and safer in clinical practice.

This article is intended for general educational purposes. Always follow the specific product IFU, applicable regulations, and institutional clinical protocols.

In 2026, several key trends are shaping TOC sampling, including low-TOC background containers, improved sample integrity, certification, automation compatibility, and updated pharmaceutical water requirements.

1. Low-TOC Background Is Becoming More Important

TOC analysis measures very low levels of organic carbon, which means contamination from the sampling container itself can potentially affect results.

Possible sources include:

• Container materials and manufacturing residues
• Cleaning agents
• Caps and septa
• Improper handling
• Environmental contamination

For sensitive applications, laboratories increasingly choose low-TOC or TOC-certified containers. Some commercial products specify container backgrounds below 10 or 20 ppb TOC and provide certificates of analysis.

This highlights an important principle: reliable TOC testing starts with sample integrity, not only the analyzer.

2. TOC Certification and Traceability

Another important trend is greater emphasis on documented container quality.

For controlled laboratory and pharmaceutical applications, useful documentation may include:

• TOC background specifications
• Certificate of Analysis (COA)
• Batch or lot identification
• Cleaning information
• Manufacturing and packaging specifications

Such documentation helps laboratories improve consistency and traceability when establishing their sampling procedures.

3. The 2026 European Pharmacopoeia Update

A significant regulatory development in 2026 is the update to the European Pharmacopoeia requirements for pharmaceutical water.

The revised Chapter 2.2.44, “Total Organic Carbon in Water for Pharmaceutical Use,” became applicable on July 1, 2026. The revision includes changes to TOC testing and introduces Method B for sterilised water for injections (SWFI).

These changes make appropriate sampling procedures and container selection increasingly relevant for laboratories working with pharmaceutical water.

4. Compatibility With Automated TOC Analysis

Laboratory automation is also influencing TOC container design.

As autosamplers become more common, containers need to match the laboratory’s equipment and workflow. Important considerations include:

• Container dimensions
• Sample volume
• Closure design
• Autosampler compatibility
• Sample identification and handling

TOC-certified containers are already available in formats designed for automated sampling systems.

5. How to Choose a TOC Sample Bottle

When selecting a TOC sample bottle, laboratories should consider more than capacity.

Low TOC Background
The container should introduce minimal additional organic carbon.

Material Compatibility
The material should be appropriate for the sample and analytical procedure.

Reliable Closure
A secure closure helps protect samples from contamination during storage and transportation.

Cleaning and Certification
Pre-cleaned or certified containers can provide better control for sensitive applications.

Instrument Compatibility
For automated testing, the container should be compatible with the laboratory’s autosampler.

6. The Future of TOC Sampling

The overall trend is moving toward better control of the entire sampling workflow, rather than focusing only on the TOC analyzer.

Future developments are likely to continue around:

• Lower container background
• Improved cleaning processes
• Better certification and traceability
• Automation compatibility
• More standardized sampling procedures

For laboratories performing sensitive TOC analysis, the sample container should therefore be considered an integral part of the testing process.

Huachenyang TOC Sampling Solutions

Huachenyang develops and manufactures laboratory and medical sampling products for professional testing applications.

Our TOC sampling solutions focus on practical requirements such as consistent manufacturing quality, reliable sealing, appropriate container design, and controlled sample handling.

For laboratories, pharmaceutical manufacturers, distributors, and OEM/ODM customers, Huachenyang provides professional sampling solutions designed for different application requirements.

Key Factors of a Reliable Stool Collection Tube

1. Low-Temperature Resistant Material

Material selection is the foundation of low-temperature performance. Polypropylene (PP) is widely used for laboratory tubes because of its chemical resistance and suitability for low-temperature applications.

However, using PP alone does not guarantee performance at a specific temperature. Polymer grade, tube thickness, structure, and manufacturing quality can all affect resistance to cracking, deformation, and brittleness.

2. Structural Integrity

Freezing can change the mechanical behavior of plastic materials. A suitable stool collection tube should maintain its shape and physical integrity throughout the intended storage temperature range.

Important design factors include:

Resistance to cracking and deformation

Consistent tube wall thickness

Stable tube geometry

Durable bottom structure

Suitable cap and tube interface

3. Reliable Sealing and Leak Resistance

Low-temperature storage can place additional demands on the tube and closure system. A secure seal helps prevent leakage, contamination, and sample loss during freezing and transportation.

For this reason, the tube and cap should be evaluated as a complete system, rather than considering the tube material alone.

4. Freeze-Thaw Performance

Some laboratory workflows involve repeated freezing and thawing. Temperature cycling can place additional mechanical stress on both the tube and its closure.

Performance evaluation may include:

• Low-temperature exposure
• Freeze-thaw cycles
• Visual inspection
• Cap integrity
• Leakage testing
• Dimensional stability

The appropriate test conditions should be based on the intended application and validated product specifications.

5. Clearly Defined Temperature Performance

“Low-temperature resistant” should not be treated as a vague marketing claim. Buyers should look for a clearly defined and validated temperature range.

For example, commercial laboratory tubes may specify storage temperatures of -80°C or lower, depending on their material, design, and intended application. Some stool preservation products also identify freezer compatibility as a product feature.

The manufacturer’s specifications should distinguish between:

Storage temperature · Operating temperature · Freeze-thaw conditions · Cryogenic storage

Choosing a Low-Temperature Stool Collection Tube

When selecting a stool sample collection tube, laboratories and IVD buyers should consider:

Huachenyang Low-Temperature Resistant Stool Collection Tube

Huachenyang Low-Temperature Resistant Stool Collection Tube is designed for stool sample collection workflows where reliable handling under low-temperature conditions is required.

Its performance can be evaluated from several key aspects, including material selection, tube structure, sealing performance, low-temperature resistance, and sample containment.

For laboratories, diagnostic companies, IVD manufacturers, and distributors, selecting a properly validated stool collection tube can help support reliable sample collection, cold-chain transportation, and laboratory processing.

Conclusion

A reliable Low-Temperature Resistant Stool Collection Tube is more than a container that can withstand cold temperatures. Material properties, structural integrity, sealing performance, leakage resistance, and validated temperature performance all contribute to dependable sample handling.

For cold-storage and cold-chain workflows, these factors provide a practical basis for selecting the right stool collection tube for laboratory and diagnostic applications.

For more than a decade, Huachenyang (HCY) has developed and supplied viral transport media and specimen collection products for diagnostic and research applications. Today, Huachenyang’s iClean Viral Transport System (VTM-RT Kit)is listed with the U.S. FDA under 510(k) K212856, with the FDA identifying Huachenyang as the manufacturer of the non-propagating transport system.

VTM Used in Peer-Reviewed Infectious Disease Research

Huachenyang VTM and specimen collection products have appeared in published research involving SARS-CoV-2 testing and viral surveillance.

In a study conducted by researchers at the University of New South Wales (UNSW) Kirby Institute, the commercial HCY-CV19-UTM, Cat. No. CY-F003-40, was specifically evaluated as a viral transport medium in SARS-CoV-2 research.

Huachenyang collection products were also documented in Qatar’s large-scale SARS-CoV-2 testing system. Research published in Scientific Reports reported the use of Huachenyang swabs for nasopharyngeal and oropharyngeal specimen collection, with samples placed in Universal Transport Medium and subsequently processed using multiple molecular testing platforms.

Other peer-reviewed studies from Qatar similarly documented Huachenyang collection products in research involving COVID-19 epidemiology, reinfection, risk assessment, and variant surveillance.

These publications demonstrate the role of Huachenyang products in real-world specimen collection and infectious disease research—not simply in laboratory product testing.

FDA 510(k) VTM for Professional Diagnostic Applications

Huachenyang’s iClean Viral Transport System (VTM-RT Kit) received FDA 510(k) substantial equivalence determination under K212856. The FDA describes the device as a non-propagating transport system intended for the collection and transport of viral specimens for laboratory culture and downstream testing.

The FDA’s current device listing continues to identify Huachenyang as the manufacturer of the iClean Viral Transport System and related VTM/UTM products.

For international laboratories, diagnostic companies, distributors, and OEM buyers, this provides an important foundation when evaluating a VTM manufacturer or viral transport medium supplier.

Built for Long-Term VTM Supply

Huachenyang combines established VTM manufacturing experience with GMP production facilities, cleanroom capabilities, quality management systems, and international regulatory certifications. Its current product range includes multiple viral transport medium formats and volumes for different specimen collection workflows.

Whether the requirement is for routine molecular diagnostics, infectious disease surveillance, laboratory testing, or OEM supply, Huachenyang provides a mature VTM kit and viral specimen collection solution designed for consistent, scalable supply.

Looking for a reliable VTM manufacturer or FDA 510(k) VTM supplier? Contact Huachenyang to discuss your VTM, UTM, specimen collection, OEM, and bulk supply requirements.